Biotricity Inc. (BTCY) - Price to Earnings Multiple

Biotricity, Inc. (BTCY) leverages AI algorithms to automate primary ECG analysis, reducing the workload for diagnostic personnel. High barriers to entry are ensured by patents for cellular IT holters and strict FDA oversight. The strategic leadership of Ashu Questra guarantees management stability amid a growing clinic client base. The current ratio is -0.30, as reflected in this price action chart.

BTCY - Biotricity P/E Multiple over the range 07/04/2022 - 08/10/2024

Analytical breakdowns for Biotricity, Inc (BTCY)

- market price and analyst price targets:

Market Price Biotricity|BTCY - Analyst Consensus Forecast

- market capitalization indicators:

Market Capitalization Biotricity Inc.|BTCY - Enterprise Value

- issuer book value statistics:

Net Assets per Single Share Biotricity|BTCY - Book Capitalization|Market Capitalization to Book Value biotricity.com|BTCY - Aggregate Company Assets

- debt and solvency information:

- earnings and market ratios statistics:

BTCY - Net Profit|Company Profit Forecast Biotricity, Inc.|BTCY - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Biotricity, Inc.|BTCY - Price/Earnings to Growth Multiple|Company Value to EBITDA Biotricity Inc|BTCY - Operating profit before deduction of amortization|Earnings per share for the trailing year Biotricity|BTCY - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months biotricity.com|BTCY - Earnings per share growth in current year|Projected earnings per share growth rate for next year Biotricity, Inc.

- company sales and revenue statistics:

BTCY - Revenue and Sales Volume|Company Future Sales Volume Biotricity, Inc|BTCY - Market Cap to Revenue|Market Cap to Expected Sales Ratio Biotricity Inc.

Comprehensive company analysis:Biotricity - BTCY

The P/E ratio reflects the actual return on investment, eliminating the blind spots of standard quarterly reporting. This metric compares the current market value of a share with the business's net profit per share. By analyzing the calculated price-to-earnings multiple, an investor assesses the degree of asset overvaluation. The trend of this indicator for Biotricity, Inc. (BTCY) confirms the high value of innovation. Cardiologists' confidence in the company's wearable devices supports the premium status of the business valuation.

Key competitors